Oligometastatic disease and stereotactic radiotherapy: Key aspects and considerations Oligometastasierung und Stereotaxie: Schlüsselaspekte und Überlegungen

Ehret F, Corradini S, Lützen U (2025)

Publication Type: Journal article, Review article

Publication year: 2025

Journal

Die Onkologie Springer

Book Volume: 31

Pages Range: 656-664

Journal Issue: 7

DOI: 10.1007/s00761-025-01728-x

Abstract

Background: Radiotherapy plays a central role in the treatment of cancer patients, with increasing significance in the management of oligometastatic disease. Stereotactic radiotherapy has established itself as an effective and safe treatment modality for intra- and extracranial metastases. It is characterized by high spatial precision, excellent tumor control rates, and a favorable risk profile. Objective: This article explores the application of stereotactic radiotherapy for treating patients with oligometastatic disease and discusses the requirements related to target volume definition, dose, treatment delivery, and imaging. Materials and methods: Various stereotactic techniques, including stereotactic radiosurgery and stereotactic body radiotherapy, are reviewed. The article particularly focuses on treatment planning and delivery, including the role of various imaging modalities. Results: Both intracranial and extracranial stereotactic radiotherapy play a central role in the treatment of oligometastatic tumors. Studies such as the SABR-COMET trial have demonstrated the benefit and safety of stereotactic radiotherapy, thus paving the way for further treatment optimization. Successful implementation of stereotactic radiotherapy relies on meeting a wide range of technical and procedural requirements, as defined by relevant professional societies. Additionally, imaging techniques such as computed tomography, magnetic resonance imaging, and positron emission tomography are crucial for staging, target volume definition, and treatment response assessment. Conclusion: Stereotactic radiotherapy has become a cornerstone in the treatment of patients with oligometastatic disease. Despite promising results, further challenges remain. Key areas include the integration of stereotactic radiotherapy into multimodal treatment strategies with the aim of maximizing synergistic effects as well as refinement of patient selection.

Involved external institutions

Charité - Universitätsmedizin Berlin DE Germany (DE) Klinikum der Universität München (LMU Klinikum) DE Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE)

How to cite

APA:

Ehret, F., Corradini, S., & Lützen, U. (2025). Oligometastatic disease and stereotactic radiotherapy: Key aspects and considerations Oligometastasierung und Stereotaxie: Schlüsselaspekte und Überlegungen. Die Onkologie, 31(7), 656-664. https://doi.org/10.1007/s00761-025-01728-x

MLA:

Ehret, Felix, Stefanie Corradini, and Ulf Lützen. "Oligometastatic disease and stereotactic radiotherapy: Key aspects and considerations Oligometastasierung und Stereotaxie: Schlüsselaspekte und Überlegungen." Die Onkologie 31.7 (2025): 656-664.

BibTeX: Download